Skip to content


  • Poster Presentation
  • Open Access

Identification of molecular apocrine breast tumours by microarray analysis

  • 1, 2,
  • 3, 4, 5,
  • 6,
  • 6,
  • 7,
  • 8,
  • 9,
  • 10,
  • 11,
  • 1, 2,
  • 2,
  • 2,
  • 12,
  • 2,
  • 1, 2 and
  • 2
Breast Cancer Research20057 (Suppl 2) :P2.11

  • Published:


  • Breast Cancer
  • Estrogen Receptor
  • Estrogen Receptor Alpha
  • Mammary Tumour Cell
  • Androgen Signalling

Previous microarray studies on breast cancer identified multiple tumour classes, of which the most prominent, named luminal and basal, differ in expression of the estrogen receptor alpha gene (ER). We report here the identification of a group of breast tumours with increased androgen signalling and a 'molecular apocrine' gene expression profile. Tumour samples from 49 patients with large operable or locally advanced breast cancers were tested on Affymetrix U133A gene expression microarrays. Principal components analysis and hierarchical clustering split the tumours into three groups: basal, luminal, and a group we call molecular apocrine. All of the molecular apocrine tumours have strong apocrine features on histological examination (P = 0.0002). The molecular apocrine group is androgen receptor-positive (AR+) and contains all of the ER-negative tumours outside the basal group. Kolmogorov-Smirnov testing indicates that oestrogen signalling is most active in the luminal group, and androgen signalling is most active in the molecular apocrine group. ERBB2 amplification is more common in the molecular apocrine group than the other groups. Genes that best split the three groups were identified by the Wilcoxon test. Correlation of the average expression profile of these genes in our data with the expression profile of individual tumours in four published breast cancer studies suggest that molecular apocrine tumours represent 8–14% of tumours in these studies. Our data show that it is possible with microarray data to divide mammary tumour cells into three groups based on steroid receptor activity: luminal (ER+ AR+), basal (ER-AR-) and molecular apocrine (ER- AR+).

Authors’ Affiliations

Swiss Institute of Bioinformatics, Lausanne, Switzerland
National Centre of Competence in Research Molecular Oncology, Swiss Institute for Experimental Cancer Research, Epalinges, Switzerland
Hôpitaux Universitaires de Genève, Geneva, Switzerland
Swiss Group for Clinical Cancer Research, St Gallen, Switzerland
European Organization on Research and Treatment of Cancer, Brussels, Belgium
Centre René Huguenin, St-Cloud, France
Centre René Gauducheau, Nantes, France
Institut Jules Bordet, Brussels, Belgium
Institut Bergonié, Bordeaux, France
Swedish Breast Cancer Group, Stockholm, Sweden
Anglo-Celtic Cooperative Oncology Group, Edinburgh, UK
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland


© BioMed Central 2005